Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQT NASDAQ:BEAM NASDAQ:CGEM NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$26.210.0%$22.74$13.06▼$31.77$3.28B1.511.50 million shs5.48 million shsBEAMBeam Therapeutics$34.14+5.1%$30.03$15.60▼$36.44$3.34B2.251.83 million shs3.49 million shsCGEMCullinan Therapeutics$15.03+4.1%$14.43$5.68▼$16.74$887.45M-0.011.16 million shs3.11 million shsTLXTelix Pharmaceuticals$10.09+1.5%$10.12$6.28▼$17.25$3.37B-0.11206,917 shs90,462 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics-0.04%+6.59%+34.41%+18.06%+91.73%BEAMBeam Therapeutics+5.11%+16.08%+29.68%+38.61%+100.94%CGEMCullinan Therapeutics+4.09%+15.79%+5.99%+17.90%+84.19%TLXTelix Pharmaceuticals+1.51%+6.77%-0.79%+15.31%-40.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$26.210.0%$22.74$13.06▼$31.77$3.28B1.511.50 million shs5.48 million shsBEAMBeam Therapeutics$34.14+5.1%$30.03$15.60▼$36.44$3.34B2.251.83 million shs3.49 million shsCGEMCullinan Therapeutics$15.03+4.1%$14.43$5.68▼$16.74$887.45M-0.011.16 million shs3.11 million shsTLXTelix Pharmaceuticals$10.09+1.5%$10.12$6.28▼$17.25$3.37B-0.11206,917 shs90,462 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics-0.04%+6.59%+34.41%+18.06%+91.73%BEAMBeam Therapeutics+5.11%+16.08%+29.68%+38.61%+100.94%CGEMCullinan Therapeutics+4.09%+15.79%+5.99%+17.90%+84.19%TLXTelix Pharmaceuticals+1.51%+6.77%-0.79%+15.31%-40.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.50Moderate Buy$34.0029.72% UpsideBEAMBeam Therapeutics 2.71Moderate Buy$46.8337.18% UpsideCGEMCullinan Therapeutics 2.63Moderate Buy$32.00112.91% UpsideTLXTelix Pharmaceuticals 2.78Moderate Buy$21.13109.37% UpsideCurrent Analyst Ratings BreakdownLatest CGEM, TLX, ARQT, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026CGEMCullinan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$37.006/8/2026CGEMCullinan Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.005/21/2026BEAMBeam Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.005/19/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.005/13/2026BEAMBeam Therapeutics Tudor PickeringSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$39.005/13/2026BEAMBeam Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $39.005/8/2026CGEMCullinan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $37.005/7/2026ARQTArcutis Biotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.005/4/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.004/28/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.004/28/2026CGEMCullinan Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $30.00(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$376.07M8.72N/AN/A$1.55 per share16.91BEAMBeam Therapeutics$139.74M25.13N/AN/A$12.20 per share2.80CGEMCullinan TherapeuticsN/AN/AN/AN/A$6.92 per shareN/ATLXTelix Pharmaceuticals$803.79M4.26$0.04 per share235.75$1.23 per share8.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$16.14M-$0.03N/A27.30N/A-0.57%-1.41%-0.59%8/5/2026 (Estimated)BEAMBeam Therapeutics-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)CGEMCullinan Therapeutics-$219.88M-$3.36N/AN/AN/AN/A-51.45%-47.64%8/6/2026 (Estimated)TLXTelix Pharmaceuticals-$7.12MN/AN/A91.73N/AN/AN/AN/A8/20/2026 (Estimated)Latest CGEM, TLX, ARQT, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million5/7/2026Q1 2026CGEMCullinan Therapeutics-$0.8359-$0.75+$0.0859-$0.75$3.67 millionN/A5/6/2026Q1 2026ARQTArcutis Biotherapeutics-$0.02-$0.09-$0.07-$0.09$103.68 million$105.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ABEAMBeam TherapeuticsN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.542.682.46BEAMBeam Therapeutics0.0916.9916.99CGEMCullinan TherapeuticsN/A10.2810.28TLXTelix Pharmaceuticals1.081.431.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ABEAMBeam Therapeutics99.68%CGEMCullinan Therapeutics86.31%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%BEAMBeam Therapeutics3.80%CGEMCullinan Therapeutics8.60%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150125.08 million113.33 millionOptionableBEAMBeam Therapeutics510102.88 million98.97 millionOptionableCGEMCullinan Therapeutics3061.46 million56.17 millionOptionableTLXTelix Pharmaceuticals1,184339.38 millionN/AN/ACGEM, TLX, ARQT, and BEAM HeadlinesRecent News About These CompaniesTelix Pharmaceuticals (TLX), United Imaging Healthcare Form Strategic Theranostics Research PartnershipJune 17 at 5:30 PM | insidermonkey.comPrediction: I think Telix shares could double in value in 2026. Here's whyJune 11, 2026 | fool.com.auTelix Pharmaceuticals Limited (TLX) Presents at 46th Annual William Blair Growth Stock Conference - SlideshowJune 3, 2026 | seekingalpha.comTelix and United Imaging Announce Strategic Theranostics CollaborationJune 2, 2026 | globenewswire.comProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026June 1, 2026 | globenewswire.comIs Telix (ASX:TLX) Quietly Assembling a Connected Oncology Platform That Reshapes Its Moat?May 29, 2026 | finance.yahoo.comTelix to Participate in William Blair Growth Stock and Jefferies Global Healthcare ConferencesMay 27, 2026 | globenewswire.comTelix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving UpMay 18, 2026 | seekingalpha.comIPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms DosingMay 18, 2026 | globenewswire.comTelix Pharmaceuticals Ltd ADR TLXMay 17, 2026 | morningstar.comMTelix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment ApproachesMay 15, 2026 | globenewswire.comTelix Issues New Shares to Complete Deferred ImaginAb Acquisition PaymentMay 10, 2026 | theglobeandmail.comMauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologic SurgeryMay 8, 2026 | businesswire.comChristian Behrenbruch Acquires 33,435 Shares of Telix Pharmaceuticals (NASDAQ:TLX) StockMay 7, 2026 | insidertrades.comNew Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCCMay 4, 2026 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 - SlideshowMay 2, 2026 | seekingalpha.comInsider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of SharesMay 1, 2026 | finance.yahoo.comTLX101-Px (Pixlumi®) MAA Accepted in EuropeApril 30, 2026 | globenewswire.comHow TLX597-Tx Phase 2 Dosimetry Data Will Impact Telix Pharmaceuticals (ASX:TLX) InvestorsApril 30, 2026 | finance.yahoo.comTelix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 TranscriptApril 30, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGEM, TLX, ARQT, and BEAM Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$26.21 -0.01 (-0.04%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$26.71 +0.50 (+1.90%) As of 06/18/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Beam Therapeutics NASDAQ:BEAM$34.14 +1.66 (+5.11%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$34.19 +0.05 (+0.15%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Cullinan Therapeutics NASDAQ:CGEM$15.03 +0.59 (+4.09%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$15.35 +0.32 (+2.13%) As of 06/18/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Telix Pharmaceuticals NASDAQ:TLX$10.09 +0.15 (+1.51%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$9.79 -0.30 (-2.96%) As of 06/18/2026 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
